2023 World Conference on Lung Cancer (Posters)-P2.13. A Novel Clinical Scoring System (EAST score) for the Prediction of Treatment Response in Limited-Stage Small-Cell Lung Cancer

P2.13. A Novel Clinical Scoring System (EAST score) for the Prediction of Treatment Response in Limited-Stage Small-Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A novel clinical scoring system called the EAST score has been developed to predict treatment response in patients with limited-stage small-cell lung cancer (LS-SCLC). The study, presented at the WCLC 2023 conference, aimed to establish criteria for predicting treatment response in LS-SCLC patients based on pretreatment factors. The research team reviewed treatment-naïve LS-SCLC patients who received platinum-based chemotherapy concurrent with thoracic radiotherapy. Using a machine learning-based approach, they identified variables that predict disease progression and established a scoring system based on these variables. The EAST score takes into account factors such as N status, serum lactate dehydrogenase (LDH), pro-gastrin-releasing peptide (ProGRP), and cytokeratin 19 fragment (CYFRA) levels. <br /><br />A total of 234 patients who completed concurrent chemoradiotherapy (CCRT) as the first-line treatment were included in the analysis. The high-risk group, identified by the EAST score (total score 2 points, N=116), showed shorter progression-free survival (mPFS) and overall survival (mOS) compared to the low-risk group (total score 1 point, N=107). The study findings suggest that patients classified as high-risk according to the EAST score may require new treatment strategies to improve their prognosis.<br /><br />The development of the EAST score is significant as there are currently no established criteria for predicting treatment response in LS-SCLC patients based on pretreatment factors. By using machine learning algorithms, the research team was able to identify and score variables that are predictive of treatment response. This scoring system can help guide treatment decisions and improve outcomes for LS-SCLC patients. Further research and validation of the EAST score may contribute to personalized treatment approaches in the future.

Asset Subtitle

Yu Ito

Meta Tag

Speaker Yu Ito

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

EAST score

treatment response

LS-SCLC

pretreatment factors

machine learning-based approach

disease progression

concurrent chemoradiotherapy

high-risk group

low-risk group

personalized treatment approaches